Autor: |
Carlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, Bruno Paiva, Monika Engelhardt, Saad Usmani, Jo Caers, Wilson Gonsalves, Fredrik Schjesvold, Giampaolo Merlini, Suzanne Lentzch, Enrique Ocio, Laurent Garderet, Philippe Moreau, Pieter Sonneveld, Ashraf Badros, Gösta Gahrton, Hartmut Goldschmidt, Sascha Tuchman, Hermann Einsele, Brian Durie, Baldeep Wirk, Pellegrino Musto, Patrick Hayden, Martin Kaiser, Jesús San Miguel, Joan Bladé, S. Vincent Rajkumar, Maria Victoria Mateos |
Jazyk: |
angličtina |
Rok vydání: |
2021 |
Předmět: |
|
Zdroj: |
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021) |
Druh dokumentu: |
article |
ISSN: |
2044-5385 |
DOI: |
10.1038/s41408-021-00587-0 |
Popis: |
Abstract Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|